Old Web
English
Sign In
Acemap
>
authorDetail
>
Divya Manoharan
Divya Manoharan
Takeda Pharmaceutical Company
Fusion protein
Cancer research
Pi
Daratumumab
Immunomodulatory drug
1
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (1)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)
2019
Blood
Shaji Kumar
Robert F. Cornell
Ola Landgren
Sikander Ailawadhi
Jack P. Higgins
Erin Willert
Roger J. Waltzman
Jianchang Lin
Yuhong Zhang
Anya Lublinsky
Ajeeta B Dash
Michael J. Hanley
Divya Manoharan
Morgan Leichter
Sean Ottinger
Richard Labotka
John Newcomb
Alexander Vorog
Show All
Source
Cite
Save
Citations (4)
1